Skip to content
Open access

Efficacy of Methika (Trigonella foenum-graecum L.) Seed Powder on Glycemic Control and Insulin Resistance in Adults with Prediabetes: Protocol for a Multicentre Randomized Controlled Clinical Trial

Nov 2026 · Intemed International Journal of Research in Integrated Medical Sciences (IJ-RIMS) · 0 citations · 3 references

Abstract

• Background Prediabetes offers an opportunity to prevent type 2 diabetes. Methika (fenugreek) seed is widely used as food and has been investigated for glycemic effects. One earlier trial in prediabetes used 10 g daily and reported less progression to diabetes, but the effect on insulin resistance remains uncertain. • Objective To compare 24 weeks of Methika seed powder plus structured lifestyle care with the same lifestyle care alone in adults with prediabetes. • Methods This proposed four-centre, parallel- group, assessor-blinded trial will randomize 240 adults aged 30–65 years with HbA1c-defined prediabetes in a 1:1 ratio. The intervention group will take 5 g of authenticated, quality-tested seed powder in water before breakfast and dinner for 24 weeks. Both groups will receive identical lifestyle counselling and follow-up. The primary outcome will be between-group difference in change in HbA1c from baseline to week 24. Key secondary outcomes will include HOMA-IR, fasting plasma glucose, two- hour glucose after a 75-g oral glucose tolerance test, weight, and adverse events. The primary analysis will follow the intention-to-treat principle with adjustment for baseline HbA1c and centre. • Discussion The trial is designed to test whether a practical dose of seed powder adds measurable benefit to lifestyle care and to examine its effect on fasting insulin resistance. The protocol does not report participant outcomes.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.